The biotechnology pipeline entering late-stage clinical development and regulatory review in 2026 encompasses some of the most commercially significant drug candidates in pharmaceutical history — Novo Nordisk's next-generation oral semaglutide, Alnylam's zilebesiran for hypertension, Regeneron's Dupixent in new indications, Vertex's suzetrigine expansion into chronic pain, and Biogen's next Alzheimer's disease programs. Pipeline analysis at the company, therapeutic area, and modality level provides essential intelligence for business development, investment, and competitive strategy decisions.
This report provides a systematic assessment of the late-stage pipeline across all ten leading biotechnology companies.
Topics Covered
• Late-Stage Pipeline by Company
• Anticipated 2026-2027 Approvals
• Pipeline by Therapeutic Area
• Pipeline by Modality
• Commercial Opportunity Assessment
• Patent Expiry and Biosimilar Risk
• Business Development Implications
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Market Overview
3. Late-Stage Pipeline by Company
4. Anticipated 2026-2027 Approvals
5. Pipeline by Therapeutic Area
6. Pipeline by Modality
7. Commercial Opportunity Assessment
8. Patent Expiry and Biosimilar Risk
9. Business Development Implications
10. Competitive Landscape
11. Regional Market Analysis
12. Strategic Conclusions
13. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Late-Stage Pipeline by Company
Table 3. Anticipated 2026-2027 Approvals
Table 4. Pipeline by Therapeutic Area
Table 5. Pipeline by Modality
Table 6. Commercial Opportunity Assessment
Table 7. Patent Expiry and Biosimilar Risk
Table 8. Business Development Implications
Table 9. Competitive Landscape
Table 10. Leading Companies — Strategy Assessment 2025
Table 11. Pipeline Assessment 2025
Table 12. Key Risks and Mitigation Strategies
Companies Profiled
BASF
Dow
Evonik
Covestro
LyondellBasell
Solvay
Clariant
Arkema
